Technology Bundle ID
TAB-3541

Preparation of Benzene-1,4-disulfonamide Derivatives Useful as Therapeutic TRPML1 Receptor Modulators for the Treatment of Lysosomal Dysfunction and Membrane Repair Disorders

Applications
Linked ID
E-084-2020-0
Lead Inventors
Haoxing Xu (University of Michigan)
Co-Inventors
Juan Marugan (NCATS)
Lu Yu (University of Michigan)
Marc Ferrer-Alegre (NCATS)
Natalia Martinez (NCATS)
Noel Southall (NCATS)
Raul Calvo (NCATS)
Xin Hu (NCATS)
ICs
This technology includes a series of novel benzene-1,4-disulfonamides that activate TRPML1 receptor. The TRPML1 receptor is a lysosomal Ca2+ channel that has been shown to be involved in controlling lysosome functions, among then the maintenance of the integrity of the plasma membrane and the modulation of autophagosome-lysosome fusion. The improved ability of the receptor to deliver Ca2+ ions to the cytosol had been correlated with its capacity to modulate autophagy and lysosome exocytosis. Therapeutically, this activation alleviates many diseases involving lysosomal dysfunction, such as lysosomal storage disorders, and membrane repair, like in muscular dystrophies.
Commercial Applications
Therapy for diseases involving lysosomal dysfunction (i.e., Gaucher’s Disease, Fabry Disease) and membrane repair (i.e., muscular dystrophies).
Competitive Advantages
First-in-class treatment for diseases with no cure and limited treatment options.

Request More Info

Licensing Contact: